Generic versus brand-name drugs used in cardiovascular diseases - Wikidata - wikimedia - TriplyDB

Generic versus brand-name drugs used in cardiovascular diseases

Generic versus brand-name drugs used in cardiovascular diseases

http://www.wikidata.org/entity/Q26775920

about

Generic atorvastatin is as effective as the brand-name drug (LIPITOR®) in lowering cholesterol levels: a cross-sectional retrospective cohort study.Comparing the Incidence of Febrile Neutropenia Resulting in Hospital Admission Between the Branded Docetaxel and the Generic Formulations.Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs.The Rotterdam Study: 2018 update on objectives, design and main results.In vitro inhibition of platelets aggregation with generic form of clopidogrel versus branded in patients with stable angina pectoris.Increased frequency of angina attacks caused by switching a brand-name vasodilator to a generic vasodilator in patients with vasospastic angina: Two case reports.

P2860

Q33912919-D745C597-5248-4102-9B4C-A0BEF76F2651 Q39537684-219B9E32-FF17-4407-8691-D8F48F091E56 Q40099619-7E70F04A-F4F2-4086-B1B4-29625878AAF5 Q47114415-3D782173-A973-4D0B-A918-81DB4BBFA259 Q47121939-2C14383F-A4E3-4027-953F-BCF158C280B8 Q49386697-A64C9702-4928-4113-8BFA-292B55AF6F95 Q54942470-E12CDE92-2921-49C3-A752-15F92A4F1419

P2860

Generic versus brand-name drugs used in cardiovascular diseases

http://www.wikidata.org/entity/Q26775920

description

2016 nî lūn-bûn

@nan

2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Generic versus brand-name drugs used in cardiovascular diseases

@ast

Generic versus brand-name drugs used in cardiovascular diseases

@en

Generic versus brand-name drugs used in cardiovascular diseases

@nl

type

label

Generic versus brand-name drugs used in cardiovascular diseases

@ast

Generic versus brand-name drugs used in cardiovascular diseases

@en

Generic versus brand-name drugs used in cardiovascular diseases

@nl

prefLabel

Generic versus brand-name drugs used in cardiovascular diseases

@ast

Generic versus brand-name drugs used in cardiovascular diseases

@en

Generic versus brand-name drugs used in cardiovascular diseases

@nl

P1433

Q26775920-960845C1-F4DE-4F02-8857-CC386CDDB5B7

P1476

Q26775920-5E90AF52-3113-4FE5-B312-10D94F769F8D

P2093

Q26775920-056950CE-55EB-458C-9285-5EB28E2BD9B1

Q26775920-456F6F7D-5CFD-48C1-94C7-06BF0E22919B

Q26775920-52AECCAE-D5AA-4BF0-98DE-A3E321677B74

Q26775920-7DE27280-B9FD-45AC-82EF-BFD55FDD8A9F

Q26775920-A429C631-7689-42EA-87A6-AD1C6F1A950E

Q26775920-FA1BAE74-0289-4079-B341-301BA8CEC414

P275

Q26775920-C767D021-1E49-45B7-B83F-2E192160CE50

P2860

Q26775920-01FD0680-AD71-44F7-8EDA-94348FC561E7

Q26775920-028DB538-1900-4274-86E0-E18310E056DA

Q26775920-059CF990-F125-41F3-8ECC-C19732904446

Q26775920-08AA1BAD-7F28-454E-84B6-2D494A3A6FFE

Q26775920-08BAB815-EE12-41CB-AEA4-7CD351C81657

Q26775920-1B8B5379-618D-4F12-8A37-2BA78365BA98

Q26775920-2D44BD42-847D-49EE-9E46-04E5E6C82CAE

Q26775920-33677F94-3883-4974-887D-20C104F1C3E4

Q26775920-35127AF9-F77A-4B2B-A1BE-761EB487DD9E

Q26775920-3A64806D-E5E3-4D8F-B68F-555101E79FDB

P2888

Q26775920-D138187B-AE6B-41ED-B483-D677DCC5040C

P304

Q26775920-85952507-FA28-4637-A765-6F63F6FB1A24

P31

Q26775920-06ca14d7-8242-4087-b6f1-900625159670

Q26775920-DF95FB4C-57F9-441C-A2E3-5F1A13CEEC96

Q26775920-F9BD5BBD-589E-422F-AB81-1F773F7E6D12

P3181

Q26775920-68D8B5F3-68EC-4F82-86BC-44823850E01E

P356

Q26775920-EA267963-F58C-4DE5-B58B-219DFA8F675E

P407

Q26775920-FDB46269-560D-44BB-9B94-D0659DDA803F

P433

Q26775920-E2C8F71C-3D7E-46AA-BE02-478D59781F7D

P478

Q26775920-BD078541-4F39-449E-8975-D8DB721B318A

P50

Q26775920-346DB113-4798-400C-80EC-CB1E944D998D

Q26775920-37D5C7A9-5329-46AB-A3B7-5C8A4F970F60

Q26775920-868096D2-F3CC-4AF5-90F7-776938933BFE

Q26775920-A3E50087-998F-4DDA-ADF3-DC56176D3791

P577

Q26775920-2B0F129C-528D-4991-BA4A-628149098C0E

Q26775920-682B312A-E766-4C8F-8437-766264D851B2

P5875

Q26775920-5685B99F-74CC-4050-A098-D7768660AFB5

P6179

Q26775920-9F910F4A-3967-4A4A-8CE5-80C597FB5A21

P698

Q26775920-C5BA1F22-6A91-4EBD-AE29-91B36505525C

P921

Q26775920-009EBD27-BF83-4972-980B-0ED6B8E71854

Q26775920-827C8F81-1CB3-4A9E-BD16-95C078AF4D6B

Q26775920-9B36871C-6E73-4724-B7C0-B1A22A60284F

Q26775920-B595A128-1D80-4149-9B79-0486514747B5

P932

Q26775920-C46A9685-964B-4E96-AEC7-73D5CB6C327A

P3181

P356

S10654-015-0104-8

P1433

European Journal of Epidemiology

P1476

Generic versus brand-name drugs used in cardiovascular diseases

@en

P2093

Carolina Marzuillo

http://www.w3.org/2001/XMLSchema#string

John P A Ioannidis

http://www.w3.org/2001/XMLSchema#string

Nikola Panic

http://www.w3.org/2001/XMLSchema#string

Paolo Villari

http://www.w3.org/2001/XMLSchema#string

Roberta Siliquini

http://www.w3.org/2001/XMLSchema#string

Walter Ricciardi

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey

LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor) in Thai hypercholesterolemic subjects -- a randomized crossover study, the first report from Thailand

Measuring the global burden of disease

Measuring inconsistency in meta-analyses

Quantitative synthesis in systematic reviews

Non-publication and delayed publication of randomized trials on vaccines: survey.

Are generic and brand-name statins clinically equivalent? Evidence from a real data-base.

Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males.

Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data.

Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.

P2888

s10654-015-0104-8

P304

351-368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4499580

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S10654-015-0104-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Lamberto Manzoli

Maria Elena Flacco

Stefania Boccia

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

285356581

http://www.w3.org/2001/XMLSchema#string

P6179

1050330207

http://www.w3.org/2001/XMLSchema#string

P698

26620809

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

pharmaceutical preparation

biomedical investigative technique

P932

4877434

http://www.w3.org/2001/XMLSchema#string